Top Buy Stocks
Sign In
NASDAQ:CPIX
Cumberland Pharmaceuticals. Stock Earnings Reports
Invest in CPIX
$5.08
-0.0100 (-0.196%)
At Close: May 23, 2025
Cumberland Pharmaceuticals. Earnings Calls
Q1 2025
| Release date | May 06, 2025 |
| EPS estimate | - |
| EPS actual | $0.160 |
| Revenue estimate | - |
| Revenue actual | 11.713M |
Q4 2024
| Release date | Mar 04, 2025 |
| EPS estimate | - |
| EPS actual | -$0.0200 |
| Revenue estimate | - |
| Revenue actual | 10.436M |
Q3 2024
| Release date | Nov 07, 2024 |
| EPS estimate | - |
| EPS actual | -$0.0200 |
| Revenue estimate | - |
| Revenue actual | 9.086M |
Q2 2024
| Release date | Aug 06, 2024 |
| EPS estimate | - |
| EPS actual | $0.0100 |
| Revenue estimate | - |
| Revenue actual | 9.849M |
Last 4 Quarters for Cumberland Pharmaceuticals.
Below you can see how CPIX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
| Release date | Aug 06, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $1.50 |
| EPS estimate | - |
| EPS actual | $0.0100 |
| Date | Price |
|---|---|
| Jul 31, 2024 | $1.43 |
| Aug 01, 2024 | $1.43 |
| Aug 02, 2024 | $1.41 |
| Aug 05, 2024 | $1.41 |
| Aug 06, 2024 | $1.50 |
| Aug 07, 2024 | $1.48 |
| Aug 08, 2024 | $1.43 |
| Aug 09, 2024 | $1.43 |
| Aug 12, 2024 | $1.42 |
| 4 days before | 4.90% |
| 4 days after | -5.33% |
| On release day | -1.33% |
| Change in period | -0.699% |
Q3 2024
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $1.20 |
| EPS estimate | - |
| EPS actual | -$0.0200 |
| Date | Price |
|---|---|
| Nov 01, 2024 | $1.12 |
| Nov 04, 2024 | $1.14 |
| Nov 05, 2024 | $1.18 |
| Nov 06, 2024 | $1.20 |
| Nov 07, 2024 | $1.20 |
| Nov 08, 2024 | $1.19 |
| Nov 11, 2024 | $1.20 |
| Nov 12, 2024 | $1.20 |
| Nov 13, 2024 | $1.18 |
| 4 days before | 7.14% |
| 4 days after | -1.67% |
| On release day | -0.83% |
| Change in period | 5.36% |
Q4 2024
| Release date | Mar 04, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $6.05 |
| EPS estimate | - |
| EPS actual | -$0.0200 |
| Date | Price |
|---|---|
| Feb 26, 2025 | $5.19 |
| Feb 27, 2025 | $4.97 |
| Feb 28, 2025 | $4.86 |
| Mar 03, 2025 | $5.14 |
| Mar 04, 2025 | $6.05 |
| Mar 05, 2025 | $6.77 |
| Mar 06, 2025 | $6.61 |
| Mar 07, 2025 | $6.37 |
| Mar 10, 2025 | $4.99 |
| 4 days before | 16.57% |
| 4 days after | -17.52% |
| On release day | 11.90% |
| Change in period | -3.85% |
Q1 2025
| Release date | May 06, 2025 |
| Fiscal end date | Mar 31, 2025 |
| Price on release | $4.41 |
| EPS estimate | - |
| EPS actual | $0.160 |
| Date | Price |
|---|---|
| Apr 30, 2025 | $4.83 |
| May 01, 2025 | $4.81 |
| May 02, 2025 | $4.50 |
| May 05, 2025 | $4.47 |
| May 06, 2025 | $4.41 |
| May 07, 2025 | $4.42 |
| May 08, 2025 | $4.50 |
| May 09, 2025 | $4.70 |
| May 12, 2025 | $5.27 |
| 4 days before | -8.70% |
| 4 days after | 19.50% |
| On release day | 0.227% |
| Change in period | 9.11% |
Cumberland Pharmaceuticals. Earnings Call Transcript Summary of Q1 2025
Cumberland Pharmaceuticals Q1 2025 Earnings Call Summary for Investors
Key Financial Results:
- Revenue Growth: Cumberland's FDA-approved brands generated $11.7 million in revenue, a 38% increase compared to Q1 2024.
- Net Profit: The company reported a net profit of $1.26 million for the quarter.
- Adjusted Earnings: Adjusted earnings reached $2.4 million ($0.16 per share).
- Cash Flow: Cash flow from operations was $3.9 million.
- Balance Sheet: Total assets stood at $70 million with $50 million in cash. Total liabilities decreased to $42 million, resulting in shareholders' equity of $51 million.
Product Highlights:
- Vibativ: A significant milestone was achieved with a $3 million payment linked to the drug’s approval in China, marking entry into a major market. The drug offers treatment for drug-resistant bacterial infections and is gaining traction amidst rising antimicrobial resistance.
- Kristalose: Revenue was $3.5 million, benefiting from new Medicaid coverage in several states. Marketing efforts are focused on better educating healthcare providers and patients.
- Caldolor: Now the only non-opioid treatment approved for pain management in infants, with increasing adoption in children's hospitals.
- Sancuso: Continued sales growth following the expansion of the oncology sales force and implementation of new patient support programs.
- Vaprisol: Awaiting resolution of FDA compliance issues to file for approval for a branded version.
Clinical Developments:
- Ifetroban: The company reported positive results from a Phase II study targeting cardiomyopathy in Duchenne muscular dystrophy (DMD), with plans to meet with the FDA for further development. Ifetroban is being evaluated in additional Phase II trials for systemic sclerosis and idiopathic pulmonary fibrosis.
Strategic Initiatives:
- Increased marketing efforts and resources allocated to enhance brand visibility and sales effectiveness across three dedicated divisions.
- Collaboration with a digital marketing agency for improved online engagement and prescription-driving strategies.
- Ongoing share purchase plans by board members to bolster confidence in the company’s prospects.
Outlook:
Cumberland Pharmaceuticals anticipates continued momentum in revenue growth, further updates from its clinical pipeline, and potential new opportunities via targeted acquisitions as it aims to build on its early 2025 achievements.
Conclusion
Cumberland is experiencing robust growth and strategic positioning within the pharmaceutical market. With promising product developments and an enhanced financial profile, the company presents itself as a potentially attractive investment opportunity. Investors are advised to monitor upcoming FDA meetings and further developments in their clinical pipeline.
Cumberland Pharmaceuticals. Earnings History
Earnings Calendar
FAQ
When is the earnings report for CPIX?
Cumberland Pharmaceuticals Inc. (CPIX) has scheduled its earnings report for Aug 04, 2025 after the markets close.
What is the CPIX price-to-earnings (P/E) ratio?
CPIX P/E ratio as of May 23, 2025 (TTM) is -23.17.
What is the CPIX EPS forecast?
The forecasted EPS (Earnings Per Share) for Cumberland Pharmaceuticals Inc. (CPIX) for the first fiscal quarter 2025 is $.
What are Cumberland Pharmaceuticals Inc.'s retained earnings?
On its balance sheet, Cumberland Pharmaceuticals Inc. reported retained earnings of $11.71 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
